Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecemotide Phase I/II in Japanese Stage III NSCLC
NCT00960115Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2008
- Primary completion
- May 2014
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tecemotide in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Dec 2008; status: completed.
02
Drugs
tecemotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00960115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00960115.